All In Biotech

NDA 020237 · Advanz Pharma

Salagen

Pilocarpine Hydrochloride · Oral

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Sep 10, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Mar 22, 1994

Approved uses

2

Original approval plus efficacy supplements

Registered trials

57

21 Phase 3, 2 recruiting

FAERS reports

2,485

1,537 serious, 101 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 23, 2026.

INDICATIONS AND USAGE Pilocarpine Hydrochloride Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 11, 1998 Supplement 7 · Efficacy ReviewLetter
  • Mar 22, 1994 Original approval · Type 3 - New Dosage Form · priority review
2 products under this application
  • SALAGEN · PILOCARPINE HYDROCHLORIDE 5MG · TABLET, ORAL · Prescription · TE AB
  • SALAGEN · PILOCARPINE HYDROCHLORIDE 7.5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Pilocarpine" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective223
  • headache199
  • pain195
  • fatigue187
  • nausea174
  • off label use154
  • dyspnoea149
  • arthralgia141
  • dizziness130
  • fall127
  • diarrhoea124
  • cough117

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200460
200562
200638
200734
200851
200973
201088
201155
201268
201377
201477
2015100
2016105
2017123
2018112
2019141
2020167
2021140
2022176
2023160
2024178
2025228
2026172

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Salagen (Pilocarpine HCl)

2024 spending

$31K

Beneficiaries

38

136 claims

Per beneficiary

$822

$1.74 per unit

View as table
YearSpending
2020$65,095
2021$35,249
2022$34,160
2023$42,840
2024$31,254

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 408 on PubMed

Sponsor: Advanz Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.